Podcasts about precision health

Michael R. Sherer explores the connection between stress, resilience, and redox health. Learn how to manage stress and enhance your resilience through precision health strategies for optimal well-being. #StressManagement #Resilience #PrecisionHealth

In this episode, we discuss everything about ACL injuries. We explore: Role of biomechanics of ACL injuryAre current ACL injury prevention programs effective? Use of Functional MRI in ACL rehabilitationWhat are the long-term consequences of ACL reconstruction? Injury risk post ACL reconstructionWant to learn more about ACL Injury incidence and prevention? Matthew Bourne and Tyler Collings recently did a brilliant Masterclass with us called “Mastering ACL Injury: From Incidence to Injury Prevention” where they go into further depth on this topic. 

On New York University Week:  Reducing the rising rate of preterm births is an important goal for the future. Laura Jelliffe-Pawlowski, professor of epidemiology and precision health at the Rory Meyers College of Nursing, looks into the data to find solutions. Dr. Laura Jelliffe-Pawlowski is a Professor of Epidemiology and Precision Health at NYU Rory […]

Discussion of the Body's Generic Response to Stress, Including Sickness Behaviors and Their Connection to Various Health Conditions with Michael R. Sherer

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, and Dr. Angela Cassano, PharmFusion Founder and owner, discuss Dr. Cassano's personal pharmacogenomics testing and how the results impacted her breast cancer treatment, the tamoxifen and CYP2D6 pharmacogenomics clinical utility research currently available, whether CYP2D6 testing for patients prior to tamoxifen is National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) recommended, and whether insurers in the United States reimburse the testing. This is a must listen for those interested in the clinical pharmacogenomics' current landscape and a pharmacist-patient's perspective about PGx testing.   

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, CEO of inGENEious RX Incorporated Pharmacogenomics Consulting, and Dr. Megan Landsverk, Scientific Director of MolDX® and Chief Science Officer of Palmetto GBA®, discuss how laboratories may overcome the challenges they face earning MolDX® coverage and reimbursement for their clinical pharmacogenomics tests. Specific to coverage determinations, the PGx veterans discuss test design, post-genotype translations, and technical assessments. Specific to reimbursement, the duo discusses evidence-based reporting and complete claim submissions. Also discussed is the importance of labs clearly defining intended use populations for tests and academic partnerships importance when labs develop and validate panels including drug-gene pairs the Clinical Pharmacogenetics Implementation Consortium and the United States Food and Drug Administration does not recognize as clinically utile for managing medications. Dr. Megan Landsverk is a Science Officer for Palmetto GBA, a Medicare Administrative Contractor (MAC) and a Science Director for the Molecular Diagnostic Services (MolDX) program developed to identify and establish coverage and reimbursement for molecular diagnostic services on behalf of Medicare. Dr. Landsverk received her PhD in Biochemistry and Molecular Biology from Baylor College of Medicine and postdoctoral training in Medical Genetics at the University of Washington. She is a board-certified Molecular Geneticist, completing her molecular genetics fellowship at Baylor College of Medicine. She has held multiple academic faculty positions and has numerous publications in the field of genetics. Prior to joining Palmetto, she served as a clinical laboratory director in academic, hospital, and commercial clinical laboratories and has experience in several genetic specialties including rare disease (pediatric and adult), cancer (somatic and inherited), and pharmacogenetics.

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, CEO of inGENEious RX Incorporated Pharmacogenomics Consulting, and Dr. Megan Landsverk, Scientific Director of MolDX® and Chief Science Officer of Palmetto GBA®, discuss how laboratories may overcome the challenges they face earning MolDX® coverage and reimbursement for their clinical pharmacogenomics tests. Specific to coverage determinations, the PGx veterans discuss test design, post-genotype translations, and technical assessments. Specific to reimbursement, the duo discusses evidence-based reporting and complete claim submissions. Also discussed is the importance of labs clearly defining intended use populations for tests and academic partnerships importance when labs develop and validate panels including drug-gene pairs the Clinical Pharmacogenetics Implementation Consortium and the United States Food and Drug Administration does not recognize as clinically utile for managing medications.  Dr. Megan Landsverk is a Science Officer for Palmetto GBA, a Medicare Administrative Contractor (MAC) and a Science Director for the Molecular Diagnostic Services (MolDX) program developed to identify and establish coverage and reimbursement for molecular diagnostic services on behalf of Medicare. Dr. Landsverk received her PhD in Biochemistry and Molecular Biology from Baylor College of Medicine and postdoctoral training in Medical Genetics at the University of Washington. She is a board-certified Molecular Geneticist, completing her molecular genetics fellowship at Baylor College of Medicine. She has held multiple academic faculty positions and has numerous publications in the field of genetics. Prior to joining Palmetto, she served as a clinical laboratory director in academic, hospital, and commercial clinical laboratories and has experience in several genetic specialties including rare disease (pediatric and adult), cancer (somatic and inherited), and pharmacogenetics.

Michael R. Sherer explores the connection between stress, resilience, and redox health. Learn how to manage stress and enhance your resilience through precision health strategies for optimal well-being. #StressManagement #Resilience #PrecisionHealth

Equitable biomarker testing access, including pharmacogenomics testing, is critical for patients to experience optimal medication therapy outcomes. Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Hilary Goeckner, Director of State & Local Campaigns - Access to Care of the American Cancer Society Cancer Action Network (ACS CAN), educate listeners about ACS CAN's mission, how it executes on its mission, accomplishments, and future goals.  This episode is a must listen for anyone who wants the latest update on the American Cancer Society Cancer Action Network's work influencing state legislatures to pass legislation to expand coverage of biomarker testing, states who have already passed legislation and those with pending legislation, and to learn how they too can advocate.   After listening to this episode, listeners will be able to describe biomarker testing's importance in healthcare; describe how the American Cancer Society Cancer Action Network is championing biomarker testing coverage legislation; name states that have passed biomarker testing legislation and those with pending legislation; know how one can contribute to the efforts to increase biomarker testing coverage. Hilary Gee Goeckner is director of state and local campaigns for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society. In this role she leads work with ACS CAN staff and coalition partners across the country to improve access to comprehensive biomarker testing, clinical trials, fertility preservation and other health care access issues. Prior to this role, Hilary served as the Kansas government relations director for ACS CAN. Before joining ACS CAN, Hilary served as director of health policy at Kansas Action for Children. She holds a bachelor's degree in anthropology and global health from Williams College and a master's degree in social work from Boston College. She lives in San Diego with her husband and two children. As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.  

Equitable biomarker testing access, including pharmacogenomics testing, is critical for patients to experience optimal medication therapy outcomes. Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Hilary Goeckner, Director of State & Local Campaigns - Access to Care of the American Cancer Society Cancer Action Network (ACS CAN), educate listeners about ACS CAN's mission, how it executes on its mission, accomplishments, and future goals.  This episode is a must listen for anyone who wants the latest update on the American Cancer Society Cancer Action Network's work influencing state legislatures to pass legislation to expand coverage of biomarker testing, states who have already passed legislation and those with pending legislation, and to learn how they too can advocate.   After listening to this episode, listeners will be able to describe biomarker testing's importance in healthcare; describe how the American Cancer Society Cancer Action Network is championing biomarker testing coverage legislation; name states that have passed biomarker testing legislation and those with pending legislation; know how one can contribute to the efforts to increase biomarker testing coverage. Hilary Gee Goeckner is director of state and local campaigns for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society. In this role she leads work with ACS CAN staff and coalition partners across the country to improve access to comprehensive biomarker testing, clinical trials, fertility preservation and other health care access issues. Prior to this role, Hilary served as the Kansas government relations director for ACS CAN. Before joining ACS CAN, Hilary served as director of health policy at Kansas Action for Children. She holds a bachelor's degree in anthropology and global health from Williams College and a master's degree in social work from Boston College. She lives in San Diego with her husband and two children. As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.  

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Josiah Allen, and Dr. Jeffrey Bishop, three PharmDs and pharmacogenomics industry veterans, discuss hot topics in the PGx industry today including the Board of Pharmacy Specialties exploring the need to establish a pharmacogenomics board specialty for pharmacists, the American Psychiatric Association's and American Heart Association's recent statements on pharmacogenomics' clinical utility, and how the need for PharmDs who are experts in genomic medicine will continue to grow as whole genome sequencing reveals additional druggable biomarkers.  

933: Through advanced data and AI, healthcare companies are transforming care with precision health, delivering earlier diagnoses and personalized treatments. At Illumina, CIO Carissa Rollins is leading the charge, modernizing the tech stack to power the future of precision health. In this episode of Technovation, Carissa discusses how technology is reshaping genomics, sharing her efforts to streamline IT, foster AI innovation, and tackle global challenges like cancer and rare diseases. Host Peter High explores Carissa's journey to becoming a CIO, her leadership in change management, and her vision for advancing precision health.

  DEXA scans promise to reveal the secrets of your body, measuring bone density, fat, and lean muscle with pinpoint accuracy. But do they work? This is a Biohacking Reviews episode. We review; products, supplements, health tech, practices... whatever is new and whatever we've been trying.  Joining me is Tim Gray again after his appearance on our Biohack Of The Year show. Follow him at @timbiohacker on instagram and get tickets to join both me and Tim at The Health Optimisation Summit in Austin.  

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Chief Scientific Officer and laboratory director for Precision Genetics, discuss pharmacists value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide his first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals. This episode is a must listen for laboratories who are vested in their pharmacogenomics testing's financial success.  After listening to this episode, the learner will be able to describe responsibilities and roles in pharmacogenomics pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists' contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories.   Dr. Jeremy Stuart has extensive experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and validation of laboratory developed tests (LDTs). He currently serves as the Chief Scientific Officer for Precision Genetics and serves as their Laboratory Director.  Dr. Stuart was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF. Dr. Stuart led the development and validation of all of Selah's molecular assays and oversaw their clinical studies. Dr. Stuart was also a member of the Agencourt Personal Genomics team, where he co-developed the SOLiD next-generation sequencing technology that was subsequently acquired by Applied Biosystems.   Before entering industry, Dr. Stuart completed his postdoctoral work at the the Harvard School of Public Health, earned his master's degree in Toxicology from the University of Minnesota, and his doctorate in Genetics & Complex Diseases from Harvard University.  As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.

Be sure to tune in to this episode of the Precision Health and PGX Podcast as Dr. Becky Winslow, Dr. Behnaz Sarrami, and Dr. Jeremy Stuart, Chief Scientific Officer and laboratory director for Precision Genetics, discuss pharmacists value as employees in clinical pharmacogenomics testing laboratories. Having employed pharmacists in his laboratories, Dr. Stuart will provide his first-hand examples to illustrate how pharmacists have benefited his laboratories. Dr. Winslow and Dr. Sarrami will also share their real-world experiences working for clinical pharmacogenomics laboratories to help the laboratory achieve its goals. This episode is a must listen for laboratories who are vested in their pharmacogenomics testing's financial success.  After listening to this episode, the learner will be able to describe responsibilities and roles in pharmacogenomics pharmacists fulfill in clinical labs, name specific real-world examples that illustrate pharmacists' contributions to pharmacogenomics in the clinical laboratory, and name education, training, and work experiences that prepare pharmacists to assume advanced practice roles in clinical laboratories.   Dr. Jeremy Stuart has extensive experience in the life science industry. He specializes in commercial operations, technology development and transfer, manufacturing design, and validation of laboratory developed tests (LDTs). He currently serves as the Chief Scientific Officer for Precision Genetics and serves as their Laboratory Director.  Dr. Stuart was part of the senior management team that completed a management buyout of Lab21 Inc. to form Selah Genomics and the subsequent sale of Selah to EKF. Dr. Stuart led the development and validation of all of Selah's molecular assays and oversaw their clinical studies. Dr. Stuart was also a member of the Agencourt Personal Genomics team, where he co-developed the SOLiD next-generation sequencing technology that was subsequently acquired by Applied Biosystems.   Before entering industry, Dr. Stuart completed his postdoctoral work at the the Harvard School of Public Health, earned his master's degree in Toxicology from the University of Minnesota, and his doctorate in Genetics & Complex Diseases from Harvard University.  As the CEO of inGENEious RX Incorporated and pharmacogenomics subject matter expert, Dr. Becky Winslow has dedicated over a decade to providing innovative solutions for pharmacogenomics stakeholders. Her extensive experience also includes directing pharmacy operations and medication safety programs across diverse clinical settings, spanning retail, hospital, long-term care, and public health. Dr. Winslow is a passionate educator, training Doctors of Clinical Pharmacy to work with molecular testing stakeholders and serving as an advanced pharmacy practice preceptor for Manchester University's Master of Science in Pharmacogenomics Program. She hosts an evidence-based educational podcast, The Precision Health and PGx Podcast, which Welp Magazine recognized as the ninth most listened to genetics podcast globally. Her involvement with prominent organizations like the Clinical Pharmacogenetics Implementation Consortium and the National Council for Prescription Drug Programs (NCPDP) PGx Task Force speaks to her expertise and commitment. Dr. Winslow frequently presents at national conferences such as The Association for Molecular Pathology and holds degrees from Campbell University.  Behnaz Sarrami, PharmD, MS, is a leading expert in pharmacogenomics and a dedicated Medical Science Liaison (MSL). She is named American Pharmacists Association's (APhA) "50 Most Influential Leaders in Pharmacy" and Medika's "Top 30 Women Transforming Healthcare". Behnaz is passionate about advancing personalized medicine to optimize treatments and improve patient outcomes, especially in underserved populations. She supports healthcare professionals through scientific training and presentations. As the host of the "Precision Health and PGx" podcast, she mentors pharmacists transitioning into MSL roles and those launching pharmacogenomics consulting careers. She earned her Master's in Biochemistry from Georgetown University and her Doctorate in Pharmacy from Creighton University. With significant contributions to research and education, she continues to drive innovation in pharmacogenomics through her work with healthcare professionals and community outreach programs.

Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute.  In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms.  Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital.   Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy.  Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.  

Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over eleven years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Kentucky Teachers' Retirement System, GenXys, and Thermo Fisher Scientific.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, has authored PGx payer databases and billing and coding algorithms and served Mintz Law as the expert medical necessity reviewer of Medicare PGx claims. She is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Winslow is an Advanced Pharmacy Practice Experience preceptor for Manchester University School of Pharmacy PharmD/Masters in PGx students and a registered trainer for the University of Pittsburgh's Test2Learn (TM) Community PGx Certificate Program. Dr. Winslow is a member of the Clinical Pharmacogenetics Implementation Consortium, the NCPDP PGx Task Force, and the Get the Medications Right Institute.  In 2021, Welp Magazine recognized Dr. Winslow's podcast, the PGx for Pharmacists Podcast, as the world's ninth most listened-to genetics podcast. Her podcast shares the top 20 most listened-to genomics podcast list with genomics podcasts created by such notable podcasters as the National Cancer Institute and the American Heart Association. The Pharmacy Podcast Network recognized Dr. Winslow in 2021 as a Top 50 pharmacy influencer. Entities frequently recruit Dr. Winslow to present PGx topics. She has presented at conferences for the National Association of Boards of Pharmacy, the National Association of Specialty Pharmacy, the Inovalon Customer Congress, and the Association for Molecular Pathology and on the Labroots' and Precision Medicine Institute's platforms.  Dr. Winslow earned her Bachelor of Science in Biology and Doctor of Clinical Pharmacy degrees from Campbell University. Lexi Wensel is a 2024 Manchester University School of Pharmacy graduate where she earned her Doctorate in Pharmacy and Masters in Pharmacogenomics. When this episode was recorded in April 2024, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy. While studying to become a pharmacist, Lexi gained practical clinical pharmacy experience while working as a pharmacy intern at both Meijer pharmacy and Marion Health Hospital.   Beyond her academic and professional endeavors, Lexi is deeply committed to giving back to the community. She serves as a board member for an organization called Guatemala Family Development where she contributed to initiatives aimed at improving healthcare access and promoting wellness in underserved communities. At the time this episode was recorded, Lexi was completing an advanced pharmacy practice experience with Dr. Becky Winslow, preceptor for Manchester University School of Pharmacy.  Dr. Mary Weissman is a clinical pharmacogenomics specialist and inGENEious RX Incorporated consultant. Since earning her Doctor of Pharmacy degree from Arnold and Marie Schwartz College of Pharmacy and completing a two-year pharmacogenomics fellowship in a clinical laboratory's medical affairs department, Dr. Weissman has applied her pharmacogenomics expertise in clinical diagnostic laboratories. At those laboratories, she has scientifically, and clinically supported pharmacogenomics stakeholders to increase clinical pharmacogenomics implementation into clinical settings. Holding titles such as clinical scientist, she has authored and developed medical content to educate healthcare providers and patients about pharmacogenomics and authored clinical decision support tools prescribers use to leverage pharmacogenomic insights in medication therapy management. Through educational trainings, white papers, presentations, and webinars, she has clarified pharmacogenomics' complexities and helped move pharmacogenomics toward a standard of care.  

In this transformative episode of Building Billions, I'm joined by Ben Greenfield, one of the world's foremost experts in biohacking and human performance. We're diving deep into a revolutionary approach to health optimization with 10X Health's precision supplements, cutting-edge genetic insights, and targeted protocols that are changing the way we think about nutrition, recovery, and personal wellness. Ben has tried it all, but what he's discovering with this precision-based system is next-level—and today, we're sharing how it can help you perform, feel, and live at your best. Throughout the conversation, Ben explains how customized nutrition, precise supplement routines, and real-time biomarker tracking can simplify and amplify your wellness. Imagine an IV drip tailored just for your body's needs or supplements built from your unique genetic profile—all in service of supercharging your energy, eliminating guesswork, and putting you back in control of your health. Ben and I discuss the freedom that comes with this streamlined system, from ditching supplement overload to traveling with only what your body actually needs to perform at its peak. If you're looking to take your wellness to a new level, this episode is a powerful entry point. Join us as we explore how personalized health can be scalable and accessible, from optimizing your day-to-day to building a foundation of health that supports long-term goals. This is about more than just feeling better; it's about creating a life where health fuels every move you make.Support the show: http://cardoneventures.comSee omnystudio.com/listener for privacy information.

Welcome back to Building Billions, I'm Brandon Dawson. I am joined by my partner Sarah Lomas, founder and CEO of REVIV Global.  In this episode, we dive into how 10X Health and REVIV Global are revolutionizing healthcare by combining personalized data, science, and technology to create tailored health solutions. Sarah shares how her vision began in 2013, starting with IV therapy, and the journey of transforming it from a niche treatment into a global modality now accessible in 46 countries. If you're looking to take control of your health and optimize your well-being, this episode will show you how precision nutrition can transform your life and change the world. With data-backed solutions and a proven system. Anyone can access personalized health strategies that improve overall wellness and longevity. As always, make sure to leave a review and share this episode with your friend & colleagues!Support the show: http://cardoneventures.comSee omnystudio.com/listener for privacy information.

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comThis week on the podcast Mikki speaks to epidemiologist Dr Terry Boyle about cancer risk and exercise. They discuss the increase in cancer cases worldwide and what might be at the heart of the increasing prevalence. They talk about how exercise can help reduce risk of cancer, but also how it can help an individual throughout their treatment and what the research tells us about its importance. They also discuss sedentary behaviour, what it means to be sedentary and why this increases the risk of cancer in the general population. And much more.https://people.unisa.edu.au/Terry.BoyleDr Terry Boyle is an epidemiologist in the Australian Centre for Precision Health at UniSA. He has a broad interest in lifestyle factors and chronic disease, with a focus on the role that physical activity and sedentary behaviour play in cancer risk, cancer survival and cancer survivorship. While he conducts research on a range of cancers, his recent studies have been on haematological cancers such as non-Hodgkin lymphoma.Terry received his PhD from The University of Western Australia in 2012, then received prestigious Fellowships from the Australian National Health and Medical Research Council (NHMRC) and the Canadian Institutes for Health Research (CIHR) which gave him the opportunity to spend two years at the BC Cancer Agency and the University of British Columbia in Vancouver, Canada. He joined UniSA in October 2017, before which he was at the Curtin University School of Public Health in Western Australia.Terry has experience in a range of epidemiological and biostatistical methods, including multiple imputation, meta-analysis, directed acyclic graphs, causal inference methods, assessment of lifestyle-related and occupational exposures and increasing participation in epidemiological studies, and is currently leading several projects involving pooling data from multiple national and international studies. Terry also lectures and consults in biostatistics. Curranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

Ikerian is pioneering the use of non-invasive retinal imaging and AI to identify biomarkers that can predict disease progression and treatment response.

In this episode of the Success Leaves Clues podcast, we interview Matt Brady, Director of Business Development at Advica Health. This company supports executives and individuals who want to personalize their healthcare journey to help improve their health outcomes. Matt discusses the services offered by Advica Health, including executive health assessments, virtual healthcare, and mental health support. He also talks about the importance of personalized healthcare and the role of precision health in improving health outcomes. Matt shares success stories and highlights the value of his work in helping individuals and their families."Preventative health and longevity are trending up." ~ Matt BradyKey TakeawaysAdvica Health helps executives and individuals navigate the healthcare system to find the best health solutions.Advica Health takes a personalized approach to healthcare, considering factors such as lifestyle, environment, and genetics.Precision health, which focuses on personalized healthcare, is an emerging field that aims to improve health outcomes.Advica Health has had success stories in detecting and treating health issues early, leading to positive outcomes.Brought to you by Aria Benefits and Life & Legacy Advisory Group

微軟在智慧醫療領域下好大一盤棋？最近釋出的foundation model目標何在？這跟上次講的權重又有何關係？真是項莊舞劍，意在沛公？ 連結： Forbes: https://www.forbes.com/sites/saibala/2024/05/22/microsoft-announces-new-foundation-model-for-digital-pathology-diving-deeper-into-clinical-medicine/ Multimodal Generative AI: the Next Frontier in Precision Health by Hoifung Poon: https://www.youtube.com/watch?v=CGyQxdM2KU8 節目內容： 若晴有要事要更正 Inside Out 2不能暴雷的討論 前情提要，權重是啥？ 對醫療AI的想像 微軟新發布的模型 Foundation model 玻片數位化 醫療填空題 最終的目標是？？？ -- Hosting provided by SoundOn

Recently, a series of papers were published in Nature and Nature journals illuminating the physiologic effects of exercise from an NIH initiative called MoTrPAC. To understand the wealth of new findings, I spoke with Professor Euan Ashley, who, along with Matt Wheeler, heads up the bioinformatics center.Earlier this week, Stanford announced Evan Ashley will be the new Chair of the Department of Medicine. He has done groundbreaking work in human genomics, including rapid whole genome sequencing for critically ill patients and applying the technology for people with unknown diseases. A few years ago he published The Genome Odyssey book. As you'll see from our conversation, he has also done extensive work on the science of exercise.Video snippet from our conversation. Full videos of all Ground Truths podcasts can be seen on YouTube here. The audios are also available on Apple and Spotify.Transcript with audio and external linksEric Topol (00:06):Well, hello, it's Eric Topol with Ground Truths, and I'm really delighted today to welcome my friend, Euan Ashley. He is the Roger and Joelle Burnell Chair of Genomics and Precision Health at Stanford. He's done pioneering work in genomics, but today we're going to talk about something very different, which he also is working in exercise. Exercise the cover of a Nature paper in May regarding this MoTrPAC, which we're going to talk about this big initiative to understand the benefits of exercise. But before I hand it over to Euan, and I just want to mention his description of the paper that he posted to summarize started with, “Exercise may be the single most potent medical intervention ever known.” So Euan welcome.Euan Ashley (01:01):Yeah, well, great. It's wonderful to be here, Eric, and so nice to see you.Eric Topol (01:06):Yeah. Well, we have a lot to talk about because exercise is a fascinating topic. And I guess maybe we'd start with the MoTrPAC, which is an interesting acronym that you all came up with. Maybe tell us a bit about that with the 800 rats and the 2,400 people and the 17,000 molecules, there's a lot there.Euan Ashley (01:24):Right, right. Yeah. Well, first of all, of course, before you do any scientific study, especially with a large number of people in a consortium, you need a good acronym. So that was where we started with the idea was to focus on the molecular transducers of physical activity. As you pointed out there at the beginning, we really don't have a more potent medical intervention, especially for prevention of disease. I mean, it's just such a powerful thing that we have, and yet we don't really understand how it works. And so, the MoTrPAC Consortium was designed to really work together, bring groups of people across the US together who all have some interest in exercise and some ability to measure molecules and really put together the world's largest study of exercise to try and start answering some of the questions about where the potency of this intervention come from.Eric Topol (02:20):So the first crop of papers, and there were several of them that came out all on the same day in Nature publications, was about the rats. The people part is incubating, but can you give us a skinny on, there was a lot there, but maybe you could just summarize what you thought were the main findings.Key MoTrPAC FindingsEuan Ashley (02:43):Yeah, of course, of course. And the MoTrPAC Consortium, I'll say first of all, yeah, large group is probably I think 36 principal investigators funded by the Common Fund. And so, it brings together large numbers of people, some of whom who spend most of their time thinking about let's say animal exercise. Some have spent a lot of time thinking about humans in exercise and many of whom think about measuring technologies. And as you say, these first group of papers were focused on the rat study, but actually the study goes much more broadly than that. But of course, there are some advantages to the animal protocols. We can look at tissue and we'll talk about that in a moment. But the humans, of course, are where we're most interested in the end. And we do have tissues coming from humans blood and adipose tissue and skeletal muscle, but those are obviously the only organs we can really access.(03:31):So there's a rat study, which is this one we'll talk about, and that's aerobic exercise and training. There's human studies that include aerobic exercise, strengths studies as well. There's a study in kids, pediatric study and then also a study of people who are very fit because here we're focusing on the change from sedentary to fit. And so that gives us the key exercise signal. So this first crop of papers was really our first look, cross-tissue, cross multi-omics, so multiple different modalities of measurement. And I think, yeah, we were like about nine and a half thousand assays, 19 tissues, 25 different measurement platforms, and then four training points for these rats. So let's talk about the rats for a minute. What do they do? So they normally live at night. They're active at night. In this study, we reverse that so that we can actually do the studies during the day.(04:25):So we reverse their at night cycle and they do their treadmill exercise over the course of several weeks. They start with about 20 minutes, and they do more every day. There's a control group of rats that just get placed on the treadmill and then don't do any exercise. And so, this is a controlled study as well. And over the course of time, we work more, it's about eight weeks in total and then two days after each of those bouts of exercise. So it's not an acute study, we measure to see where we are. So we also have this time trajectory of exercise. So what did we find? I mean, I think the first thing I would say, we talked about just how potent exercise is. It's very, very clear from looking at all these tissues that when you exercise regularly, you are just a different person, or in this case a different rat.(05:15):Like literally every tissue is changed dramatically and some in quite surprising ways. So I give you a couple of the things that surprised me or that I thought were most interesting. The first thing was this question of how does exercise actually work? Because exercise is a stress. You go out and you pound the pavement or you're on the bike or whatever, and then your body recovers. And so, there's been this idea, it's referred to as hormesis, this idea that some of the benefit of exercise might come from this recurrent stress. So your body learns how to deal with stress. And so given that we were very interested that this heat shock response was so prominent across multiple tissues. So heat shock proteins are molecular chaperones and they take care of protein folding to make sure it's appropriately done and they prevent protein aggregation. And when proteins need degraded because they're damaged, the heat shock system jumps in.(06:10):So perhaps not surprising, but pretty interesting that the heat shock proteins were very prominent part of the stress response to exercise. And remember, this is not acute exercise, so these are benefits that are built up over time, so that was one. A surprising one to me, the adrenal gland. So we're used to thinking of adrenaline as an epinephrine, as a stress hormone, but actually we saw dramatic changes in the adrenal gland and we don't necessarily think too much. You think about the exercising muscles, you think about the heart, we think about the lungs, when we think about exercise, you don't necessarily think that you're changing your adrenal gland, but it was one of the most changed tissues. The immune system was a common upregulated system. We saw that. And in fact, some of the tissues in which the immune genes were most changed were somewhat surprising.(07:02):So the small intestine, for example, was a place where there was a highest enrichment of immune mediated pathways. And then some tissues changed pretty early, like the small intestine changed after just one or two weeks of training other tissues like the brown adipose tissue. It was more like seven or eight weeks of training before we saw the real changes in there. So just one or two little things that struck out, but I think this really the first molecular map of exercise. So we're looking across the whole system across multiple modalities of measurement across multiple tissues.Simulating StressEric Topol (07:34):So as far as understanding the benefits of exercise, does this tell us that it really does simulate stress that it's conditioning the body to deal with stress as reflected by the various points you just summarized?Euan Ashley (07:51):Yeah, I think that is exactly right. I mean, part of what we were trying to understand was in what way are you changed after you do exercise regularly? And I think if we think about things that are positive, then the ability to deal with stress at a cellular level, quite literally repair mechanisms seems to be a big part of it. The other aspect that was interesting is that when you're measuring this many analytes, you can also compare that with disease. And so, we understand that exercises is preventive benefit against disease. So in some cases, and this was work highlighted by my colleague Maléne Lindholm in the mitochondrial paper that came along with the main paper and she looked with a team across all mitochondrial changes across all of the tissues of the cell. So these are the workhorses of the individual cells that like the batteries inside the cells of the mitochondria.(08:54):And we saw big changes across, it's not surprisingly, but it's the energy source for cells, big changes across many tissues. But interestingly for two specific really important diseases, a liver disease in one case and type 2 diabetes on the other, it was very clear that the training upregulated a network that was exactly the opposite of that of the disease. And so, it really was intervening in a way that was very specifically opposite to the way we know disease mechanisms go. So it does seem like, I mean people talk about an exercise pill. I think this shows that that is just not going to be possible. There may be ways we could mimic some elements of exercise, but there's no pill. This is a multisystem, multi-tissue, multidimensional response to exercise.Eric Topol (09:44):Yeah, I think it's really important. That was one of the questions I was going to ask you is whether this would ever be simulated by a drug. And I think you already answered that, and the fact that it's so comprehensively sweeping across every organ and all these different signals, tens thousand plus signals across them, it's really striking. We never really understood the benefits of exercise and not that it's all resolved by any means. Some of the things that were interesting too was the sex specific findings. Maybe you want to comment about that because we don't spend enough time thinking about how sex does have a big effect on physiology.Sex-Specific FindingsEuan Ashley (10:24):Yeah, I mean that's a really good point and one that I think was really underlined for us at every corner, every turn of the analysis here. So really no matter which measurement modality, no matter which tissue, no matter which point of training, if we just asked these computer models to sort of separate the data according to the prominent signals without giving it a clue of what to do, the so-called unsupervised models, then sex basically came out every single time. So I think you say you're absolutely right that we so often overlook the difference. For years we've said, oh, it's too expensive to do animal studies in both sexes, so we'll just pick one. And males were picked more often. But there are plenty of studies that were just females, and I mean that clearly is wrong, and we are really, sometimes it appeared like we're almost dealing with two different species.(11:18):They were so different. But I think we can also learn from what those differences were. Interestingly, some of them were most profound in adipose tissue, so in fat, and that was the case both at rest, sedentary and amplified by exercise. So we saw big difference between females and males in relation to the kinds of signals that were prominent in the white adipose tissue. So this fat storage tissue, for example, in sedentary females, insulin signaling and the trigger to make fat and store fat was very prominent. But whereas in the males, even before any exercise, the fat signals were more related to metabolism, and we could have wild speculation about in evolutionary terms why that might be. Obviously, males and females have different biological many differences in their biology and obviously thinking about hormone systems and specifically pregnancy of course. And so, we could probably come up with some theories. In reality, all we know now are these observations were found and they're pretty interesting and they show us that we really always need to think separately about both sexes and look at both independently.Eric Topol (12:39):Well, and the other thing that you already pointed out, but I just want to underscore, you can't do this stuff in people. You can't just do fat biopsies and whatnot. So I mean, the fact that you can do this multi-omic, multi-organ type assessment is just really an extraordinary opportunity for learning. And while we're on the white fat story just briefly, we would rather have a lot more brown fat, but as we age, and I assume it's the same in rats, they don't have much as they get older brown fat. Does exercise help us get more brown fat or are we just stuck with the white adipose tissue?Brown vs White FatEuan Ashley (13:21):Yeah, well, it certainly allows us to have less of a white adipose tissue, and I think it's potential that our brown adipose tissue maybe more functional, and for those who are listening who are not familiar, I mean these really are different colors that relate to the actual color of the tissue, but the color is different because the brown adipose tissue contains lots of mitochondria and lipid droplets, and the brown adipose is there to help essentially generate heat. It has a very different function in a way, but even white adipose tissue that we think of as just being about storing energy, people think of fat as a very metabolically neutral or inert tissue, but in reality it's not. It's signaling. It's constantly, it's a tissue that's as alive as any other and not just a storage for excess energy, but exercise definitely appears to alter both in this sexually dimorphic way as we noted already and clearly both in a positive health way where I think the makeup of the brown tissue is different. The white tissue, there is less of it obviously with exercise, which is something that is well known, but not new here for the first time. But still important to have seen that even in the rats.Eric Topol (14:49):And there's even, we talked a moment go about drugs, but there are some molecules that are thought to be able to help convert white to brown fat that are understudy and we'll see if they get anywhere that's interesting. But also, you talked about aerobic exercise and with us both being cardiologists, and I know throughout my earlier part of my career, we only talked about aerobic exercise. There was no such thing as strength training, and we even discouraged that or we never talked about it. Now we know how important strength training is and not just strength and resistance training, but balance and posture and all these other things. I assume you can't study that in the rats.Euan Ashley (15:32):Well, it's not impossible. This study of course is about endurance, but as you say, and there are some models, I mean I've even seen models in trying to trigger flies to do strength training.Eric Topol (15:46):Wow, I didn't know that.Intensity of ExerciseEuan Ashley (15:46):That somewhere, yeah, we'll have something, there are various methods of making animals hang off things, and this was treadmill. So it's a fairly routine and standard I think part of a rat's life to run. So this was not so different. As we mentioned at the beginning in the human study, we do have a strength portion and the endurance portion, which I think is very important because as you say, the benefits of exercise are found really across both of those. And indeed, as you say, flexibility and other often neglected element of physical activity. But yeah, those benefits are there for both aerobic exercise and endurance. And in fact, they are perhaps even higher for higher intensity exercise. Although I think we don't necessarily recommend everybody do higher intensity exercise. I don't think it's necessary to get most of the benefits of exercise, but there is some additional benefit.(16:42):One of my favorite facts, I think I first saw it probably on a presentation a few years ago, but I looked up the original and recalculated it. But if you look at this very big study of half a million people and look at their physical activity over the course of years and correlate it with their likelihood of being alive or being dead, then it was clear that one minute of exercise bought you five minutes of extra life. And I just thought that was just a really interesting way of putting it essentially. And actually it's a little more, if you did high intensity exercise, one minute would give you seven or eight minutes of extra life. So I tell this to my patients when they come in and tell me they don't have enough time to exercise. I said, oh, well, one minute of exercise. I'm not very popular when I tell them that, but anyway.Eric Topol (17:30):You think it's true. Do you think it's based on good data?Euan Ashley (17:34):Well, the data is large, I mean half a million people. I think we've also seen it currently since the early fifties when we were first doing the London bus conductor study that Jerry Morris did that you will know well, where he compared bus conductors on the London to the bus drivers and found a significantly reduced cardiovascular mortality among the conductors because they were on their feet all day up and down stairs and the driver otherwise in the same environment the drivers were sitting. So I think we have a wealth of epidemiologic correlative evidence that exercise leads to a greater length of life, greater longevity, maybe more than for anything else. The causal evidence is less of course, but we do have causal evidence too. There are enough randomized trials and now increasingly some genetic causal evidence that helps us understand that this is really a causal link and that we actually can change our outcome if we do additional exercise.Mental Health BenefitEric Topol (18:32):Oh, and I don't question at all what you said about the enhancing healthy aging health span and even possibly lifespan. I just wondered about the one to five ratio if we could assert that. I mean that's really interesting and it's a good motivating factor because as you well know by that WHO criteria, one out of four people aren't even close to the modest exercise recommendation. So we got ways to go to get people to spruce up exercise. Now speaking of people, I do want to come back to MoTrPAC and the people plan, but I do want to before that get your sense about a couple of really fascinating studies. So earlier this year there was a study of every exercise study that's been looking at mental health along with SSRIs that name drugs that are used for mental health. And it was a pretty fascinating study. I think I'm just going to pull it up. They looked at everything that this is for depression, walking, jogging, yoga, strength training, SSRIs. And what was fascinating is that dancing, walking, jogging, it made the drugs look like a joke. They didn't seem to work at all. So this was 218 studies with over 14,000 people. And so, I don't know that enough people recognize this fact that this Prozac nation and all this stuff about the SSRIs, but exercise seems to do wonders for people who are depressed, anxious, stressed. What do you think about that?Euan Ashley (20:26):Yeah, I mean it's exactly right. I mean I think that it's very clear from the data and as you mentioned, you and I tend to focus first on the cardiovascular benefit, which is very significant, potentially 50% reduction in risk, but there are similar sorts of numbers when you look at mental health and exercise as an intervention for mental health has been very well studied and has these really dramatic benefits. And I think even if we go in the more general population and think about the fact people talk about a runner's high or an exercise high, and many, many of us, myself included, feel that. And a few years ago, I started exercising every morning and now if I don't do that, I really feel like I'm missing something, there's something in the chemistry of my brain is not quite right. And so, I think that benefit for those who have mental health issues is also very much felt and is real at the brain chemical signaling level and with this few adverse effects as exercise has, I do think we need to think of it earlier and more prominently for almost every disease.Eric Topol (21:40):Yeah, you're I think alluding to the opioids that are released with exercise and addiction to exercise, which is what ideally if everybody could be addicted to exercise, that might help a lot of things. As you mentioned in your post that I started with, “its benefits in prevention outstrip any known drugs: 50% reduction in the cardiovascular disease, 50% reduction in risk of many cancers, positive effects on mental health that we just discussed, pulmonary health, GI health, bone health, muscle function. You name it.” So you said it really well there, and that was just one recent report that substantiated the mental health. I want to also mention another report that's fascinating on cancer that is a publication again recently was looking at both mice and people with pancreatic cancer. And what was fascinating about it is the more exercise of the mice and in the people, the more survival that is from pancreatic cancer, which as we both know and all the listeners will know, is that one of the worst cancers of humankind. So the affecting cancer is fascinating. Now can you dial up your immune system response with exercise?Euan Ashley (23:02):Yeah, I think you can. And I think we were at some level expecting to see it because it's certainly a known thing, but I think again, this is able, our ability to measure it in this study is just much deeper than we've ever had in any study before. And so, I think when we think about mechanisms that might relate to reduced risk of cancer, as you say, we think first of the immune system and that signal was there in many places. As we mentioned at the very beginning, sometimes to me in some slightly surprising places like the small intestine, we don't think of that necessarily as the seat of immune activation, but I think what we were doing, what we were seeing is those signals really across all the tissues and ultimately the immune system is a distributed system. It senses in multiple places and then obviously has implementation.(23:53):Now exactly in what way we've turned up our T or B cells, for example, to be able to attack those cancers or support the therapy that's been given. I don't think we understand that yet. But actually, you bring up another great point, which is part of MoTrPAC was to create this molecular map and analyze it and put the first analysis out there. So that's what we've done, but just as big and maybe even a bigger reason is that to release the data and to make it accessible for everyone and anyone in the world as of the moment this paper came out can go to our data portal at https://motrpac-data.org/ and download the data and then use that in their own work. They can do their own analysis just of this data, but also what we're hoping is that they'll start to use the data, let's say as control data for a cancer study or for a diabetes study or for others. So we really hope it'll fuel many, many more studies over many years from now.Eric Topol (24:52):Yeah, I mean that open science approach to applaud that it's so vital and amplifies what's good to come out of this really important initiative. Now you mentioned the opioids and proteins that are secreted with exercise, exerkines is a term that's used and also I guess these extracellular vesicles (EVs) not electric vehicles. Can you tell us about exerkines and EVs and are they part of the story?Euan Ashley (25:25):Yeah, and actually in the human study there's a specific exosome analysis that will be reported there. Yeah, I think that when we think about this multi-system nature of exercise, and one of the fascinating things was to be able to have these omics in multiple tissues and think about how those tissues were signaling to each other. So obviously there are some tissues that are more fundamental to the exercise response. We think of those as the skeletal muscles. They literally the effectors of our ability to exercise. And I think we think of the heart and lungs in particular in the blood system of course, but we were seeing changes everywhere and it's one of the reasons we were seeing changes everywhere is that there are molecules that are essentially secreted into the circulation or locally by these exercising muscles, exerkines that have a number of positive benefits.(26:21):And it is possible if there's some mechanism towards mimicking some of what exercise does with a drug, then that's a good place to go look for it. And I think that this will also fuel those thoughts. I think we both, we'd agree that there isn't going to be one pill that will do all the magic of exercise, but I think there are probably things we will learn from the study where we say, well, this was a very positive benefit and it seems to be mediated by this particular molecule, and that's something that could potentially lead towards a more targeted drug. I think we'll definitely get into that and understanding just we're systems people are, again, I think we think in physiology, so when we see the tissues like connecting and communicating with each other, I think that just makes a lot of sense from a systems perspective.Eric Topol (27:10):Now getting onto the forthcoming work that's going to come out with the 2,400 people and the different groups that you mentioned, I wonder if it'll include things like biologic aging with DNA methylation, will it have immunomes to characterize the differences in the immune system? What kind of things might we expect? Obviously, you can't get tissue, but for blood samples and things like DNA methylation, can we get some more illumination on what's going on?Euan Ashley (27:41):Yeah, I think we can. And of course, ultimately the human is the organism we're most interested in. Interestingly, I'll say interestingly as well, we can get some tissue and huge credit to both the investigators who are doing this and most credit of all to the individuals who agreed to join the study because they actually agreed not just to give blood samples, but actually to give skeletal muscle samples. So a biopsy of the skeletal muscle and a biopsy of the fat pad. So we will actually have two other tissues in the humans, not this obviously vast range that we talked about with the rat study, but we'll have those two other tissues and we'll also then have the rat data, which is the other great thing. So we'll have this foundational insight that we can then bring to the human study with the humans as we mentioned before as well, we'll have not just endurance but strength trained, we'll have it in kids as well, and we'll have these higher intensity exercise.(28:36):I think we will be able to connect with this, as you mentioned, longevity literature or the health span literature where we can start to think about DNA methylation. We do have genomes of course, on all of the individuals. It won't be a study powered because it's thousands individuals, these kinds of numbers. It won't be powered to give us genetic predictors. If you think about the studies had to be hundreds of thousands of people and even more now in order to give us, let's say common variant predictive. So we won't be able to do that, but there's lots of connections we'll be able to make by being much closer to the effector systems, which is to say the proteins and the metabolites and those signals we're already seeing are very significant. And so, I do think that there'll be a lot of new signals that we'll see that are specific to humans that will connect into other bodies of work, for example, the longevity, and we'll see those in blood and I hope that we'll be able to connect also the skeletal and adipose tissue data as well.Eric Topol (29:37):One of the things that would be wonderful to connect if you can, our mutual friend and your colleague at Stanford, Tony Wyss-Coray has these organ clocks that have been validated now in the UK Biobank, and then you can see what's happening with the wealth of plasma proteins that have been validated across each organ. So without having to do tissue, you might get some real insights about organ clock. So I mean, I'm really looking forward to the people part of this. When do you think the next wave of output's going to come from MoTrPAC?Euan Ashley (30:11):Well, I think that another element of the study is that we have ancillary studies, so investigators who said, I want to be able to use MoTrPAC data and use some of the infrastructure, but I'm looking for funding for my parallel study. So some of those ancillary studies will start to come out over time, which I think will be interesting and will be a very good place to see the breadth of activity that has been triggered by this one investment. The human study is coming along. We're actually just now plotting the last two or three years of the consortium. Time has really gone by pretty fast, and we've had to scale back just a little bit on the total numbers of humans, but it should still be, I think probably the largest multi-omics study of humans that there has been. And I think if we were going to plan one of those, then planning it to study around exercise definitely, definitely makes sense. So there is some data that was, of course Covid happened in the middle of this, so that was a major challenge with hitting the original numbers. But there's some data from the humans who were recruited before Covid hit that will be coming out and hopefully in the relatively near future. And then the big study may still be a year or two away to get it finished. But after that, as we say, we hope that the data and the science will continue for I hope decades beyond just the collection of this repository.Eric Topol (31:41):That's great. You mentioned Covid and I did want to ask you about the folks with Long Covid who are suffering from fatigue and exercise intolerance and what do you think about this kind of vicious cycle? Because if they could exercise, it could help them get into a better state, but because of not being able to, it's just a negative feedback loop. Any thoughts about that?Exercise and the Immune SystemEuan Ashley (32:13):I mean, it's such a good point and it's one of course that we talk to many of our patients where they, for whatever reason, sometimes it's because they are struggling with weight or they're struggling with other mobility challenges, and now we have this very large population who are struggling with fatigue. As you mentioned, it's a group that we were somewhat familiar with because of flu and because EBV and other, I mean long syndromes were something we were familiar with. They were just kind of rare, and so there wasn't really much work done on trying to understand them. Now as you've, I think articulated better than anyone, we have this entire population of people because of the scale of Covid who have these symptoms that are recognizable for the first time and including on your podcast, you have had folks on that have discussed it. Some of the insights that have happened from actually applying science, I wish there was an answer that was buried here in MoTrPAC and maybe there is, there will certainly have data from before and after the pandemic and maybe there may be some insights that we can bring to that.(33:20):I certainly think we have a lot of insights on the interaction between infection and the immune system. We talked about the potential for the immune system to be ramped up in that potentially being one of the mechanisms through which this might help cancer. There's also the idea of, and we've seen this with the effect of vaccination on Long Covid, which perhaps surprisingly does seem to have a significant benefit for at least a group of people. The assumption there is that we're ramping up the immune system and it's having that extra effect on whether it's actually pools of hidden antigens that are hidden from the immune system or whether it's some other element of the kind of ensemble attack of the immune system that is related to the symptoms. But either way, I think we feel that having a more ramped up immune system is likely to be beneficial, but at a very real human level, the point you made is the hard one. If you're really fatigued and you just feel you can't exercise, then these benefits are just out of reach and you're in this negative feedback cycle and breaking that cycle is hard. I think we try to suggest people do it very gradually because you can get a lot of benefit from just a little exercise and that's something, so that's some way, and then hopefully people can build up slowly over time, but it's a really big challenge.Eric Topol (34:43):I hope we can crack the case on that because I know that's something holding these folks back and there's just millions of them out there. Now let's talk about the healthy folks that you see in clinic. What do you advise them about exercise besides the fact that one minute we'll give them five minutes, but do you advise them to have X amount of aerobic and X amount of resistance and in the general person, what would you tell them patients?Euan Ashley (35:13):Yeah, yeah, I do. So I suggest habit is everything. So I suggest to people that they exercise every day or take one day of rest because I think there is some benefit with the stress response and having a rest day. So I suggest five or six days a week if possible, trying to get into a habit of doing it. So pick a time that works for you. It could be first thing in the morning, could be last thing at night. The jury's out on when the best time to exercise is. What it's very, very clear is that getting the exercise done is what counts. Accumulating time is also what counts. I mean, if you're not someone who wants to pull on running kit and go out running, that's fine, but accumulating steps, accumulating physical activity and moving is key. So not having people overshoot being too ambitious, but if they're really motivated to do something, then I would say five or six times a week a combination of both aerobic and endurance exercise and strength.(36:07):Usually I suggest two to one in favor of aerobic exercise, but it's also possible I think to alternate and do more 50/50. I think the key is that both are featured and then I think a bit neglected because to be honest, our data on it is just not as good, but flexibility is really critical and particularly in the senior population and for a group who sit all day long, I think for those two groups in particular, flexibility is really under-recognized as a major component. Even in my cardiology clinic, I've helped several patients just get over their back pain by teaching them some back stretching exercises. And so, I think that's neglected. So I suggest all three of those and really it's whatever works for the individual. I think the key is to find, it might be working in a group format, it might be going to a gym, it might just be taking regular walks. The key is to get moving and not sit. Get moving and do it regularly and get into the habit.Individualized Exercise?Eric Topol (37:09):Yeah, and actually on that point about potential individualization in the future, I noticed that you and some people that worked in your lab and others, Svexa is a company you started for exercise. Can you tell us about that?Euan Ashley (37:26):Yeah, this was a PhD student who was in my lab many years ago and was doing his PhD joint between the Karolinska Institute in Sweden. And of course, the country of Sweden has a long history of exercise physiology, science, and as he came out, we realized that there was the potential for optimization of training for individuals, whether they're recreational athletes or elite athletes in the Olympics. And he was interested in taking this and running with it, which he did. So the company originally Silicon Valley exercise analytics, but shortened now to Svexa builds, builds products to help people basically individualize their training. And we work, say with recreational athletes on an individual basis, we work with a lot of Olympic athletes in multiple countries and the technology building the sort of magic sauce that many of these coaches even up to and including Olympic coaches have into a format that can be spread and amplified to many more people is one of the themes.(38:29):And when we think about professional athletes and the company works with a number of well-known brand name teams that are in soccer leagues and in national football league here in the US and really across professional sport, what we're thinking of there is optimizing performance. Of course, all the teams want to win, but reducing injury is the other key part because the management of load, these are professional athletes, they're getting up every day in training and they're trying to optimize their training and their coaches are trying to do that. And it's been a fairly data free zone over the years, but meanwhile, we actually have learned a lot about how to measure individuals and how to measure what training works, and if you think about a team that might be paying 20 million a year for their star player, if that player gets injured, that's a pretty expensive thing. And so, investing a little bit in understanding the training load, helping the coaches understand the data, and then adapting that to each individual in the team so that their chance of injury is lower. That's really a lot of what the company spends its time thinking about.Eric Topol (39:36):Now, do you use sensors like lactate and glucose and AI of their body and how do you figure this stuff out?Euan Ashley (39:45):Yeah, all of that is possible. It's interesting, some sports have a kind of culture of measurement. For example, lactate measurements, which as your listeners will know, is it requires a small blood sample usually from the finger or from the ear lobe. Some sports like swimming have done that for years. But other sports, it's just not been so much in the culture. So I would say that from the company perspective, we work with whatever data is available and we'll make recommendations if people want to think about wearable devices. Of course, the digital era is around us, and you can get a lot from just a standard watch in terms of heart rate, heart rate variability in terms of accelerometry and movement. You can do a lot with just that, but there's lots more. Many of these teams have GPS signals so they know how far an athlete moves in a given game, how fast they move, how much time they spend at tool speed versus medium speed.(40:37):So we can use all of that. And as you say, yes, AI for sure is a large part of what we do and a couple of different ways actually. One is just for the analysis of the data, but another is this idea of scaling expertise. This is something in the AI community. I know you talked about a lot where you could take the expertise of let's say a physician with a very specialized practice or an Olympic coach for a marathon runner and basically make a language model that contains that expertise and then allow many people, thousands of people potentially to benefit from that expertise that we'd otherwise be sort of locked up with next available appointment is 18 months down the road, but if your AI can potentially reflect a lot of what you have, a lot of your expertise, not all of it, we hope, but probably a lot of it, then that expertise could potentially be offered much more broadly. And if it's to help people exercise more and more effectively, it's going to be a lot of good that I think can come from that.Eric Topol (41:33):Yeah. No, it's really interesting. I think there's unlimited opportunities there. It's like Moneyball to the 10th power. It's like all this data that's in sports that gets me, I guess to the last question I had for you, and that is the elite athlete or athlete hard. These are people that are working out endurance just to the max, these extremists, and they're prone to heart issues like atrial fibrillation. Why is that? What's going on with these people that they exercise too much? Is it just the lack of moderation, extremism or what's going on?Euan Ashley (42:10):Yeah, well, so it's interesting that of course you mentioned atrial fibrillation. I think that really is the only downside of exercise, even fairly extreme exercise that I've ever been, I think that we've ever had really good data for. And I would say that over the years, and I've been one way or another touching the exercise science world for 20 years and more now and certainly have been asked very often, surely these people are doing themselves harm. And the reality is, although every now and again there's a study that shows some harm or they measure troponin, they measure something in the blood and someone says, oh, they must be doing themselves harm. It's been very hard to find it. The reality is atrial fibrillation though really is, especially for those ultra endurance athletes, that's for real. And that is, we don't know that it's associated with a mortality impact necessarily, but it's definitely annoying and it slows down.Endurance Athletes and Atrial Fibrillation(43:03):We have athletes who come in and say they're cycling up a hill and suddenly they drop their power drops and they realize they've gone into atrial fibrillation. I used to play basketball with someone who would go into atrial fibrillation, so I would know when to try and get past him once he went into atrial fibrillation. But that's a real thing, and I think one of your questions was why I think I have a lot of close friends who are ultra endurance runners. They're among some of the most chilled and happiest people I know. I think those benefits of exercise are what they're enjoying, and I think there's a literature on addiction to exercise. So there is a small number of people who get addicted to that feeling and addicted to the chemical matter in their brain and can't stop, and they really do get to the point of doing themselves harm.(43:53):Fortunately, I think that's a pretty small number. And overall, although there are many consequences of chronic long-term exercise, almost all of them seem to be positive. The other one that you and I are probably very familiar with is the calcium scans that we see now much more often, it's common for people who've exercised a lot to have more calcium in their hearts. Now they have a lower risk of that. They have lower risk of heart attacks in general, one or two studies muddied the waters just a little. But in general, it's very clear they have very positive health benefits and yet they have more calcium. So they are an exception. We've seen in our sports cardiology clinic here at Stanford, several athletes every month, several will come in with this finding and we are explaining to them, this doesn't mean they have the same risk as someone who hasn't exercised at that level who would have that calcium score. It does seem to be very different, and it may be that there's a stabilization of those plaques in the arteries. I don't think we understand the biology that well, but we understand the epidemiology quite well, which is that their risk really is still low.Eric Topol (44:59):Yeah, no, it's interesting that there's still some uncertainties there and MoTrPAC may help guide us or at elucidate some of them. I guess it does bring up one other thing I got to get to with you because we didn't really get to the question of moderate to higher intensity, not to the level of the ultra exercises, but if you just do steps or do you sweat like hell, where do you draw the line? Or is that really part a function of age and ability? When you recommend exercise, because obviously you're rational and there's others out there that are exercising three or four hours a day and they're going to extreme craziness, but just in a reasonable thing, do you think just telling people who are 70 that walking is good enough or do you try to encourage them to push it?Euan Ashley (45:59):Yeah, I do encourage people to push it a bit because I think there's clear evidence that higher intensity, some degree of higher intensity exercise really does provide more benefit. But I think my main message first is because for most people, the potential of moderate versus high is in the distance and in the future for most people, we need to get them off the couch and get them on their feet. So my emphasis is that you can go a long way with just a little movement, even a little standing. And then I think if they're really getting into the habit and really doing some exercise then, and if they don't have a prior history of let's say, heart attack or other medical issues that might make high intensity exercise risky, if they don't have those, then I absolutely do get to the point where I recommend some amount of higher intensity exercise, because I think there is some evidence that it has a little extra benefit.Eric Topol (46:51):Oh, that's great. Well, this is the most in-depth conversation I've ever had with anybody on exercise, so Euan I really appreciate it. I mean, I knew you from all your work in genomics of course, and we've had some overlap from time to time, but the exercise stuff is fantastic. Did I miss anything?Euan Ashley (47:09):No, I don't think so. Just underline again to anyone who's listening if they're interested to play with this data, it's very much out there. It's a tool for the world, and they can go to https://motrpac-data.org/ and even you can do some analysis without downloading any data either. If you just have a favorite gene or a favorite protein, you can type that in and take a look at some of the tools we have there. But yeah, really appreciate the conversation and very fun to chat about what has been a really, really fun project.Eric Topol (47:39):Well, thank you and all the folks at MoTrPAC, all the hard work and of course the funding that got it going to give it that runway of several years. So we'll look forward to more. I hope to convene with you again when some of the other studies come out, and thanks so much.*****************************************************Thanks for listening, reading or watching!The Ground Truths newsletters and podcasts are all free, open-access, without ads.Please share this post/podcast with your friends and network if you found it informativeVoluntary paid subscriptions all go to support Scripps Research. Many thanks for that—they greatly helped fund our summer internship programs for 2023 and 2024.Thanks to my producer Jessica Nguyen and Sinjun Balabanoff for audio and video support at Scripps Research.Note: you can select preferences to receive emails about newsletters, podcasts, or all I don't want to bother you with an email for content that you're not interested in. Get full access to Ground Truths at erictopol.substack.com/subscribe

In this episode of The Root Cause Medicine Podcast, we discuss food intolerances, food allergies, and gut health. They dive into: 1. Food Issues Symptoms 2. Food Allergy Versus Food Sensitivity 3. How Food Affects Your Intestines Dr. James LaValle is an internationally recognized clinical pharmacist, author, board-certified clinical nutritionist, educator in integrative and precision health, and founder of Metabolic Code Enterprises. He has over thirty-five years of experience integrating natural and integrative therapies into various medical and business models. Dr. LaValle has also authored sixteen e-books and twenty books, was named one of the “50 Most Influential Pharmacists” by American Druggist magazine, and was one of only nine Americans selected to serve under Senator Harkin to participate in the inaugural Dietary Supplement Education Alliance & Dietary Supplement Information Bureau.

David Hellerstein, MD, is professor of clinical psychiatry and an award-winning writer of  nonfiction and fiction. Books such as Heal Your Brain: How the  New Neuropsychiatry Can Help You Go from Better to Well (2011); A Family of  Doctors (1994), a memoir of 5 generations of doctors in his family; Battles of Life  and Death, an essay collection; and two novels, Loving Touches and Stone Babies. And recently The Couch, the Clinic, and the Scanner. A must read! A top psychiatric researcher, he has done cutting-edge studies on new treatment  for depression, using MRI imaging to discover brain circuits related to illness and  the effects of treatment. For the past five years, his research has focused on new  psychedelic treatments of depression and other disorders, using psilocybin and  other long-banned drugs.   

David Hellerstein, MD, is professor of clinical psychiatry and an award-winning writer of  nonfiction and fiction. Books such as Heal Your Brain: How the  New Neuropsychiatry Can Help You Go from Better to Well (2011); A Family of  Doctors (1994), a memoir of 5 generations of doctors in his family; Battles of Life  and Death, an essay collection; and two novels, Loving Touches and Stone Babies. And recently The Couch, the Clinic, and the Scanner. A must read! A top psychiatric researcher, he has done cutting-edge studies on new treatment  for depression, using MRI imaging to discover brain circuits related to illness and  the effects of treatment. For the past five years, his research has focused on new  psychedelic treatments of depression and other disorders, using psilocybin and  other long-banned drugs.   

May 14: Today on TownHall Sue Schade, Principal at StarBridge Advisors talks with Paul Browne, SVP and Chief Information Officer at Henry Ford Health System. As he shares his journey through the healthcare technology industry and the strategic plan at Henry Ford, key questions surface. How are we redefining patient and workforce engagement in this digital age? How does the idea of 'precision health' disrupt traditional healthcare models and what does this mean in building a more personalized patient-care approach? And importantly, as we innovate healthcare cost structures and experience labor cost rises, how does the role of CIO evolve in terms of workforce development and succession readiness? Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

A Precision Health Approach Post-Treatment Comorbid Diabetes in Cancer With Marilyn Hammer by i3 Health

Episode Summary: In recognition of National DNA Day, April 25, 2024, Dr. Mary Weissman, Miss Courtney Harmon, and Dr. Becky Winslow discuss clinical pharmacogenomics resources, what pharmacogenomics information they provide, and how to navigate and utilize the pharmacogenomics information to answer a prescriber's clinical question about pharmacogenomics' relationship to an adverse drug event.  Listeners interested in learning a step-wise approach to using the Food and Drug Administration's (FDA's) Table of Pharmacogenetics Associations and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling, the Clinical Pharmacogenetics Implementation Consortium's (CPIC's) database, and the Pharmacogenomics Knowledgebase (PharmGKB) to demystify pharmacogenomics' role in adverse drug events will not want to miss this Precision Health and PGx Podcast episode.  Biographies: Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over ten years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry to reduce barriers holding pharmacogenomics back from becoming a standard of care including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Acutis Diagnostics, Kentucky Teachers' Retirement System, and GenXys.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Mary Weissman is a pharmacogenomics science, clinical utility and reimbursement expert and inGENEious RX Incorporated team member.  After earning her PharmD from the Arnold and Marie Schwartz College of Pharmacy, Dr. Weissman completed a two-year pharmacogenomics fellowship with a clinical diagnostic lab. Upon completing her academic training in pharmacology and pharmacogenomics, Dr. Weissman embarked on a journey to apply her expertise in clinical diagnostic laboratories and has held several key scientific and clinical roles in pharmacogenomics laboratories. Through informative presentations, training sessions, papers, and webinars, she has helped clarify pharmacogenomics' complexities and highlight its potential to revolutionize medication management strategies for pharmacogenomics' stakeholders. Miss Courtney Harmon is graduating from Manchester University's Pharmacy and Pharmacogenomics programs in 2024.  She serves as a P4 liaison for Manchester University's chapter of Industry Pharmacists Organization (IPhO) and she is interested in pursuing a career in industry pharmacy. She has worked for Walgreens pharmacy for the last eight years.  References: 1. Table of pharmacogenomic biomarkers in drug labeling. U.S. Food and Drug Administration. Published August 10, 2023. Accessed February 1, 2024. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling  2. Table of pharmacogenetic associations. U.S. Food and Drug Administration. Published October 26, 2022. Accessed February 1, 2024. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations  3. CPIC. Cpicpgx.org. Accessed February 1, 2024. https://cpicpgx.org  4. PharmGKB. PharmGKB. Accessed February 1, 2024. https://www.pharmgkb.org Keywords: #pharmacogenomics #ingeneiousrx #PGx #pharmacists #precisionhealthandpgxpodcast #pharmacypodcastnetwork #pharmacogenetics #genetics #sources #resources #FDA #CPIC #PharmGKB

Episode Summary: In recognition of National DNA Day, April 25, 2024, Dr. Mary Weissman, Miss Courtney Harmon, and Dr. Becky Winslow discuss clinical pharmacogenomics resources, what pharmacogenomics information they provide, and how to navigate and utilize the pharmacogenomics information to answer a prescriber's clinical question about pharmacogenomics' relationship to an adverse drug event.  Listeners interested in learning a step-wise approach to using the Food and Drug Administration's (FDA's) Table of Pharmacogenetics Associations and the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling, the Clinical Pharmacogenetics Implementation Consortium's (CPIC's) database, and the Pharmacogenomics Knowledgebase (PharmGKB) to demystify pharmacogenomics' role in adverse drug events will not want to miss this Precision Health and PGx Podcast episode.  Biographies: Before founding inGENEious RX Incorporated, a boutique pharmacogenomics consulting firm, Dr. Winslow directed pharmacy business operations and clinical pharmacy programs in retail, hospital, long-term care, and public health pharmacies for Walmart Stores, Community Health Systems, Neil Medical Group, and the North Carolina Department of Health and Human Services. Since founding inGENEious RX over ten years ago, Dr. Winslow has worked with numerous distinguished vendors in the pharmacogenomics industry to reduce barriers holding pharmacogenomics back from becoming a standard of care including Translational Software, Admera Health, Genemarkers, National Association of Chain Drug Stores, Acutis Diagnostics, Kentucky Teachers' Retirement System, and GenXys.  A sought-after pharmacogenomics subject matter expert, Dr. Winslow, is an authority in pharmacogenomics access and reimbursement and specializes in business strategy consulting for pharmacogenomics stakeholders.   Dr. Mary Weissman is a pharmacogenomics science, clinical utility and reimbursement expert and inGENEious RX Incorporated team member.  After earning her PharmD from the Arnold and Marie Schwartz College of Pharmacy, Dr. Weissman completed a two-year pharmacogenomics fellowship with a clinical diagnostic lab. Upon completing her academic training in pharmacology and pharmacogenomics, Dr. Weissman embarked on a journey to apply her expertise in clinical diagnostic laboratories and has held several key scientific and clinical roles in pharmacogenomics laboratories. Through informative presentations, training sessions, papers, and webinars, she has helped clarify pharmacogenomics' complexities and highlight its potential to revolutionize medication management strategies for pharmacogenomics' stakeholders. Miss Courtney Harmon is graduating from Manchester University's Pharmacy and Pharmacogenomics programs in 2024.  She serves as a P4 liaison for Manchester University's chapter of Industry Pharmacists Organization (IPhO) and she is interested in pursuing a career in industry pharmacy. She has worked for Walgreens pharmacy for the last eight years.  References: 1. Table of pharmacogenomic biomarkers in drug labeling. U.S. Food and Drug Administration. Published August 10, 2023. Accessed February 1, 2024. https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling  2. Table of pharmacogenetic associations. U.S. Food and Drug Administration. Published October 26, 2022. Accessed February 1, 2024. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations  3. CPIC. Cpicpgx.org. Accessed February 1, 2024. https://cpicpgx.org  4. PharmGKB. PharmGKB. Accessed February 1, 2024. https://www.pharmgkb.org Keywords: #pharmacogenomics #ingeneiousrx #PGx #pharmacists #precisionhealthandpgxpodcast #pharmacypodcastnetwork #pharmacogenetics #genetics #sources #resources #FDA #CPIC #PharmGKB

Cafer's Psychopharmacology| Dr Jason Cafer is an assistant Professor of Clinical Psychiatry at University of Missouri-Columbia. He is certified by the American Board of Psychiatry and Neurology and also the American Board of Preventive Medicine. In 2007 he founded Iconic Health, a medical informatics startup that obtained angel round funding. He was Principal Investigator for Phase I and II Small Business Innovation Research (SBIR) grants for "Online Rural Telepsychiatry Platform" that was funded by the United States Department of Agriculture. He is the inventor of United States Patent which was the subject of an SBIR grant awarded by the Department of Health and Human Services for "Medication IconoGraphs: Visualization of Complex Medication Regimens". Visit his website to learn more about Cafers' Psychopharmacology. https://www.cafermed.com/blog Behnaz Sarrami, MS, PharmD  Becky Winslow, PharmD  Dr. Jason Cafer, MD  

This week, I am joined by Dr. Lloyd Minor, the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University. Dean Minor talks about the transformative potential of AI in healthcare delivery, research, and diagnostics. We discuss its nuanced pros and cons, including impacts on accessibility, safety, and efficiency. Dean Minor examines AI's benefits in drug discovery, Precision Health, and early disease detection. He elaborates on wearables and the shift towards a proactive approach, integrating tools like virtual reality into medical education and emphasizing nutrition in training. Addressing ethical considerations and industry influence, we delve into the regulatory framework driving transformative changes. We also explore groundbreaking diagnostics, envisioning a future revolutionized by growing and 3D printing organs, and much more.  Enjoy! Show notes + MORE Watch on YouTube Newsletter Sign-Up  Today's Sponsors: Brain.fm: Focus music for productivity—listeners can get 30 days FREE 

Welcome to part two with Dr. Cam McDonald on the "Everyday Epigenetics: Raw, Real, Relatable," myself host Susan Robbins is joined by Dr. Cam McDonald from Precision Health Alliance. We are continuing our deep dive into the fascinating world of epigenetics, exploring how genetics, BMI, lifestyle, and environmental factors intricately influence our health. Today we introduce the different healthtypes and bringing and understanding to each.Join us as we uncover the six distinct health types. From the competitive and adrenaline-driven Activators to the nurturing and community-oriented Guardians, each type offers valuable insights into personalized health approaches. Whether you resonate with the goal-oriented Crusaders or the empathetic Connectors craving social connection, understanding your unique biological makeup is key to unlocking your full potential.Discover how your genetics, lifestyle, and environmental factors shape your health journey. From preferred exercise routines to dietary needs and optimal daily rhythms, we explore the nuances of each health type, providing actionable strategies for achieving vibrant health and vitality.Don't miss this captivating exploration into the world of epigenetics and personalized wellness. Tune in to "Everyday Epigenetics: Raw, Real, Relatable" for an enlightening conversation that could transform your approach to health and well-being.RESOURCES:Connect with Dr. Cam McDonald:Instagram: https://www.instagram.com/drcammcdonald/Website: https://precisionhealthalliance.org/Show Links:Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksSHOW NOTES: healthyawakening.co/episodeConnect with Susan:Schedule a FREE consultation, send an email to susan@healthyawakening.coFaceboook: https://www.facebook.com/susanrobbinshealthyawakeningInstagram: @susanrobbins_epigeneticcoach

Once you start working with epigenetics you can't unlearn it. Health doesn't have to be difficult. Learning about yourself is the key!  Welcome to episode 1 of “Everyday Epigenetics: Raw. Real. Relatable.” podcast! This is the first part of a two-part series with Dr. Cam McDonald. Cam is a leading figure from Precision Health Alliance. In this groundbreaking first episode, they delve deep into how understanding our genetics can pave the way for a future free of chronic disease by 2050. Discover the amazing interplay between exercise physiology, nutrition, and lifestyle medicine, and how small changes tailored to our unique genetic makeup can lead to significant health improvements.Cam and Susan are talking all things personalized health. Cam's journey started when he realized his goal was to try to prevent disease rather than putting bandaids on health issues. They discuss how when someone understands their body and their needs then you can understand how your body reacts to it's environment.  The goal is to feel more like yourself so that you an be less reactive to your environment. Even the healthiest and most effective diets need to be tailored to the individual. The conversation dives into some very interesting stats about workout results, and the effectiveness of various strategies. The conversation also explores the effectiveness of cognitive behavioral therapy, the significance of understanding children's genetic predispositions, and the revolutionary use of AI technology in crafting health recommendations.Susan and Cam share personal anecdotes and real-life examples, making the complex world of epigenetics relatable and understandable.This episode is a call to action for listeners to embrace the uniqueness of their genetic blueprint and make informed decisions for a healthier life.  Whether you're a health enthusiast, a parent, or someone looking to take control of your health journey, "Everyday Epigenetics. Raw. Real. Relatable" offers insights into how personalized health strategies can lead to remarkable transformations.RESOURCES:Connect with Dr. Cam McDonald:Instagram: https://www.instagram.com/drcammcdonald/Website: https://precisionhealthalliance.org/Show Links:Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksSHOW NOTES: healthyawakening.co/episode1Connect with Susan:Schedule a FREE consultation, send an email to susan@healthyawakening.coFaceboook: https://www.facebook.com/susanrobbinshealthyawakeningInstagram: @susanrobbins_epigeneticcoach

Towny Robinson is the CEO of JayMac Pharmaceuticals and the inventor of EnLyte and EnBrace HR. He is a national expert on Methylation Biochemistry/Genetics and Psychiatric Disorders. Visit his website to learn more: www.enlyterx.com/about-enlyte www.enlyterx.com/about-enlyte Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.  

Towny Robinson is the CEO of JayMac Pharmaceuticals and the inventor of EnLyte and EnBrace HR. He is a national expert on Methylation Biochemistry/Genetics and Psychiatric Disorders. Visit his website to learn more: www.enlyterx.com/about-enlyte www.enlyterx.com/about-enlyte Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc.  

This week on the Think Fit Be Fit podcast, Jennifer Schwartz and Angela DalMolin invite Dr. Matt Dawson of Wild Health Diagnostics to discuss the intersection of health, fitness, and cutting-edge technology. Jenn, Angela, and Dr. Dawson discuss the future of medicine, the power of personalized health optimization, and the importance of motivation in achieving optimal results. Dr. Dawson shares his insights on the role of technology and the need for a holistic approach to healthcare. He also touches on the benefits of coaching and accountability in achieving long-term health goalsTopics discussed:Wild Health leverages an individual's DNA, lifestyle data, and AI analytics to personalize health optimization.The company aims to reconnect people with ancient wellness wisdoms while utilizing the latest in health technology.Motivation is a critical factor in achieving significant health outcomes through personalized health plans.Wild Health's upcoming AI app aims to further democratize health optimization by providing personalized advice based on comprehensive personal data.The Think Fit Be Fit podcast focuses on empowering listeners with knowledge and critical thinking to take control of their fitness and health.Wild Health is offering our listeners a discount code for 20% off a subscription WH20 f to their Precision Health services: https://www.wildhealth.com https://www.instagram.com/wildhealthmd/ SUBSCRIBE: Subscribe to the podcast to make sure you never miss an episode.You can find us on a variety of podcast apps:SpotifyPandoraiHeartRadioAmazon MusicTuneInGoogle podcastsConnect with Jennifer Schwartz:Studio websitePersonal WebsiteInstagramTwitterConnect with Angela DalMolin:https://www.instagram.com/rethinking_fitness/Support the Show:Hydrogen is used by health professionals as a powerful antioxidant and the #1 tool to fight inflammation. Studies show therapeutic potential in cancer, diabetes, digestive and heart issues, and essentially every organ and system in the body. Because hydrogen is the smallest...

In this captivating episode of the Thrive State Summit, Dr. Kien Vuu dives deep into the realms of consciousness, human evolution, and transformational leadership with visionary Matt Riemann. They explore the fusion of spirituality, health, and technology, aiming to guide humanity towards its inherent truth and eradicate chronic disease by 2050. Discover the groundbreaking approach of using AI for personalized health insights and how understanding your unique biological makeup can lead to a life of fulfillment and purpose. Don't miss these profound insights and practical tips to embark on your path of conscious evolution.    Check out this amazing AI technology at www.ph360.me/drv   

EPISODE SUMMARY Join scientist and mindset & high-performance coach Claudia Garbutt and Andrew Herr, the founder and CEO of Fount, as they discuss new ways to optimize health & performance.   In this episode, we talk about:  - A data-driven, personalized approach to human performance & longevity - Dopamine management for focus & productivity - The future of health   EPISODE NOTES Andrew Herr is the Founder & CEO of Fount. Fount runs the most comprehensive and customized health and performance programs in the world. Previously, Andrew led human performance and biotech strategy efforts for the U.S. military, from running R&D strategy efforts to getting Navy SEALs ready to deploy.  Andrew's work has been profiled and published by Wired, Joint Force Quarterly, Defense News, and others, and he has been honored as a Mad Scientist by the U.S. Army (twice), as a Fellow by the Synthetic Biology Leadership Excellence Accelerator Program, and as an Emerging Leader in Biosecurity.   Andrew also serves as an Adjunct Assistant Professor at Georgetown University, where he teaches about human performance and advanced military technology.   Links: https://www.fount.bio/ https://twitter.com/andrewherrbio https://www.linkedin.com/in/andrew-herr/   Click this link to listen to the full episode on your favorite podcast player and if you enjoy the show, please leave a rating & review: https://linktr.ee/wiredforsuccess.   Help me keep this show ad-free and awesome: Hit subscribe and join the tribe! THANK YOU for your support! 

Listen to this episode of People of Precision Health to learn about: How to engage communities in health disparities research with underserved communities A shift in thinking about how researchers should address health disparities research How defining catchment areas can hold community hospitals accountable in their resourcing of cancer care and cancer research Learn about the Chickahominy TRUTH research projectWatch a video about the Chickahominy TRUTH project

In this episode of Talking HealthTech, Peter Birch is joined by guest Oliver Canfell, a Research Fellow in Digital Health at The University of Queensland and clinically trained as an Accredited Practising Dietitian. In this episode, Oliver shares his journey from being confronted with the reality of patients struggling with obesity to their realisation of the need to treat people earlier and pursue a PhD in research to prevent unhealthy weight. The conversation covers the successes and challenges of public health, the concept of precision in public health, and the role of digital health in predicting and preventing health issues. Key Takeaways:- The concept of precision in healthcare is about using new types of data to target individual factors, whether social, behavioural, genomic, or related to the environment and infrastructure.- Digital health, particularly AI, allows for precise identification of individuals or groups at risk, enabling early intervention and prevention of health issues.- The shift from a break fix system to a predict-prevent system focused on consumer health is the next healthcare revolution.- Real-time data generation through digital health tools can provide more efficient and precise insights for policy-making and intervention.- The prevention of chronic diseases is a major global health challenge, and digital health has the potential to play a significant role in preventing and managing these diseases.Check out the full episode and show notes on the Talking HealthTech website.Loving the show? Leave us a review, and share it with someone who might get some value from it.Keen to take your healthtech to the next level? Become a THT+ Member for access to our online community forum, quarterly summits, and more exclusive content. For more information, visit talkinghealthtech.com/thtplus.

Chegou o momento do já tradicional episódio duplo sobre o IgNobel, que tem como missão "honrar estudos e experiências que primeiro fazem as pessoas rir e depois pensar", com as descobertas científicas mais estranhas do ano.Esta é a primeira de duas partes sobre a edição 2023 do prêmio, trazendo as categorias Química & Geologia, Literatura, Engenharia Mecânica, Saúde Pública e Comunicação.Confira no papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.> OUÇA (43min 47s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*PARCERIA: ALURAAprofunde-se de vez: garantimos conhecimento com profundidade e diversidade, para se tornar um profissional em T - incluindo programação, front-end, data science, devops, ux & design, mobile, inovação & gestão.Navegue sua carreira: são mais de 1300 cursos e novos lançamentos toda semana, além de atualizações e melhorias constantes.Conteúdo imersivo: faça parte de uma comunidade de apaixonados por tudo que é digital. Mergulhe na comunidade Alura.Aproveite o desconto para ouvintes Naruhodo no link:https://bit.ly/naruhodo_alura*CATEGORIAS PARTE 1PRÊMIO DE QUÍMICA E GEOLOGIA [POLÔNIA, REINO UNIDO]Jan Zalasiewicz, por explicar por que muitos cientistas gostam de lamber rochas.REFERENCE: “Eating Fossils,” Jan Zalasiewicz, The Paleontological Association Newsletter, no. 96, November 2017. palass.org/publications/newsletter/eating-fossilsPRÊMIO DE LITERATURA [FRANÇA, REINO UNIDO, MALÁSIA, FINLÂNDIA]Chris Moulin, Nicole Bell, Merita Turunen, Arina Baharin e Akira O'Connor por estudar as sensações que as pessoas sentem quando repetem uma única palavra muitas, muitas, muitas, muitas, muitas, muitas vezes.REFERENCE: “The The The The Induction of Jamais Vu in the Laboratory: Word Alienation and Semantic Satiation,” Chris J. A. Moulin, Nicole Bell, Merita Turunen, Arina Baharin, and Akira R. O'Connor, Memory, vol. 29, no. 7, 2021, pp. 933-942. doi.org/10.1080/09658211.2020.1727519PRÊMIO DE ENGENHARIA MECÂNICA [ÍNDIA, CHINA, MALÁSIA, EUA]Te Faye Yap, Zhen Liu, Anoop Rajappan, Trevor Shimokusu e Daniel Preston, por reanimar aranhas mortas para usá-las como ferramentas de agarrar mecânico.REFERENCE: “Necrobotics: Biotic Materials as Ready-to-Use Actuators,” Te Faye Yap, Zhen Liu, Anoop Rajappan, Trevor J. Shimokusu, and Daniel J. Preston, Advanced Science, vol. 9, no. 29, 2022, article 2201174. doi.org/10.1002/advs.202201174PRÊMIO DE SAÚDE PÚBLICA [COREIA DO SUL, EUA]Seung-min Park, por inventar o Toilet Stanford, um dispositivo que usa uma variedade de tecnologias, incluindo uma tira de teste de urinálise, um sistema de visão por computador para análise de defecação, um sensor de impressão anal emparelhado com uma câmera de identificação e uma ligação de telecomunicações, para monitorar e analisar rapidamente as substâncias que os seres humanos excretam.REFERENCE: “A Mountable Toilet System for Personalized Health Monitoring via the Analysis of Excreta,” Seung-min Park, Daeyoun D. Won, Brian J. Lee, Diego Escobedo, Andre Esteva, Amin Aalipour, T. Jessie Ge, et al., Nature Biomedical Engineering, vol. 4, no. 6, 2020, pp. 624-635. doi.org/10.1038/s41551-020-0534-9REFERENCE: “Digital Biomarkers in Human Excreta,” Seung-min Park, T. Jessie Ge, Daeyoun D. Won, Jong Kyun Lee, and Joseph C. Liao, Nature Reviews Gastroenterology and Hepatology, vol. 18, no. 8, 2021, pp. 521-522. doi.org/10.1038/s41575-021-00462-0REFERENCE: “Smart Toilets for Monitoring COVID-19 Surges: Passive Diagnostics and Public Health,” T. Jessie Ge, Carmel T. Chan, Brian J. Lee, Joseph C. Liao, and Seung-min Park, NPJ Digital Medicine, vol. 5, no. 1, 2022, article 39. doi.org/10.1038/s41746-022-00582-0REFERENCE: “Passive Monitoring by Smart Toilets for Precision Health,” T. Jessie Ge, Vasiliki Nataly Rahimzadeh, Kevin Mintz, Walter G. Park, Nicole Martinez-Martin, Joseph C. Liao, and Seung-min Park, Science Translational Medicine, vol. 15, no. 681, 2023, article eabk3489. doi.org/10.1126/scitranslmed.abk3489PRÊMIO DE COMUNICAÇÃO [ARGENTINA, ESPANHA, COLÔMBIA, CHILE, CHINA, EUA]María José Torres-Prioris, Diana López-Barroso, Estela Càmara, Sol Fittipaldi, Lucas Sedeño, Agustín Ibáñez, Marcelo Berthier e Adolfo García, por estudar as atividades mentais de pessoas que são especialistas em falar ao contrário.REFERENCE: “Neurocognitive Signatures of Phonemic Sequencing in Expert Backward Speakers,” María José Torres-Prioris, Diana López-Barroso, Estela Càmara, Sol Fittipaldi, Lucas Sedeño, Agustín Ibáñez, Marcelo L. Berthier, and Adolfo M. García, Scientific Reports, vol. 10, no. 10621, 2020. doi.org/10.1038/s41598-020-67551-z*REFERÊNCIASThe 33rd First Annual Ig Nobel Prize Ceremonyhttps://www.youtube.com/watch?v=P9UQi0ORXv4Naruhodo #29 - O que é e como acontece o déjà vu?https://www.youtube.com/watch?v=MsgpP0CWrZsNaruhodo #141 - Cheirar pum faz bem a saúde?https://www.youtube.com/watch?v=ISe5ObqFjT0Naruhodo #375 - Por que cutucamos o nariz?https://www.youtube.com/watch?v=N_iB-EHHh5gNaruhodo #384 - Por que tomamos choque quando encostamos em certas coisas?https://www.youtube.com/watch?v=DhKsqKRHwswNaruhodo #389 - Por que repetir palavras deixa elas estranhas?https://www.youtube.com/watch?v=JKN89pAb10UNaruhodo #397 - Por que ficamos entediados?https://www.youtube.com/watch?v=FAZ9BPv_6O4Naruhodo #151 - Especial Prêmio Ig Nobel 2018 - Parte 1 de 2https://www.b9.com.br/shows/naruhodo/naruhodo-151-especial-premio-ig-nobel-2018-parte-1-de-2/Naruhodo #152 - Especial Prêmio Ig Nobel 2018 - Parte 2 de 2https://www.b9.com.br/shows/naruhodo/naruhodo-152-especial-premio-ig-nobel-2018-parte-2-de-2/Naruhodo #202 - Especial Prêmio Ig Nobel 2019 - Parte 1 de 2https://www.b9.com.br/shows/naruhodo/naruhodo-202-especial-premio-ig-nobel-2019-parte-1-de-2/Naruhodo #203 - Especial Prêmio Ig Nobel 2019 - Parte 2 de 2https://www.b9.com.br/shows/naruhodo/naruhodo-203-especial-premio-ig-nobel-2019-parte-2-de-2/Naruhodo #254 - Especial Prêmio Ig Nobel 2020 - Parte 1 de 2https://www.b9.com.br/shows/naruhodo/naruhodo-254-especial-premio-ignobel-2020-parte-1-de-2/Naruhodo #255 - Especial Prêmio Ig Nobel 2020 - Parte 2 de 2https://www.b9.com.br/shows/naruhodo/naruhodo-255-especial-premio-ignobel-2020-parte-2-de-2/Naruhodo #302 - Prêmio IgNobel 2021 - Parte 1 de 2https://www.youtube.com/watch?v=tos9wQyGSTINaruhodo #303 - Prêmio IgNobel 2021 - Parte 2 de 2https://www.youtube.com/watch?v=D3QDkBx7_osNaruhodo #355 - Prêmio IgNobel 2022 - Parte 1 de 2https://www.youtube.com/watch?v=KIx5uHKgHLsNaruhodo #356 - Prêmio IgNobel 2022 - Parte 2 de 2https://www.youtube.com/watch?v=WIOVn1hDt8s*APOIE O NARUHODO PELA PLATAFORMA ORELO!Um aviso importantíssimo: o podcast Naruhodo agora está no Orelo: https://bit.ly/naruhodo-no-oreloE é por meio dessa plataforma de apoio aos criadores de conteúdo que você ajuda o Naruhodo a se manter no ar.Você escolhe um valor de contribuição mensal e tem acesso a conteúdos exclusivos, conteúdos antecipados e vantagens especiais.Além disso, você pode ter acesso ao nosso grupo fechado no Telegram, e conversar comigo, com o Altay e com outros apoiadores.E não é só isso: toda vez que você ouvir ou fizer download de um episódio pelo Orelo, vai também estar pingando uns trocadinhos para o nosso projeto.Então, baixe agora mesmo o app Orelo no endereço Orelo.CC ou na sua loja de aplicativos e ajude a fortalecer o conhecimento científico.https://bit.ly/naruhodo-no-orelo

Dave Arnold, Director of the NextGen Precision Health Initiative, talks about how the new facility has made a big difference in Mizzou research and recruiting on the latest Brad's Bites.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: CLICK HERE---Episode Overview: As a passionate and trailblazing digital health physician entrepreneur with a mission to disrupt the healthcare landscape, our next guest combines cutting-edge technologies and insights from diverse industries to empower individuals to live healthier, longer, and more productive lives.Dr. Ravi Komatireddy, Founder and CEO of Daytona Health, joins us to explore his company's groundbreaking approach of leveraging personalized coaching and behavior change techniques to drive positive health transformations. Join us to learn how Dr. Komatireddy's expertise in translational medicine and digital health startups has helped him build his fast-growing company, as well as the inspiring discussion we had about navigating healthcare data, harnessing the power of AI, and driving innovation in the pursuit of a better world. Let's go!Episode Highlights:Dr. Komatireddy shares his journey as a clinician, translational medicine, digital health, and previous startupsWhy Dr. Komatireddy launched Daytona HealthThe challenges of navigating the sea of data in healthcareThe importance of combining technology with human persuasion to turn data into actionable insightsThe potential of machine learning and AI in the coaching spaceAbout our Guest: Ravi Komatireddy, MD, MCTI is a digital health entrepreneur, former Chief Medical Officer, and Board-certified physician with a solid reputation of leveraging cutting-edge technologies and innovations to disrupt the healthcare landscape. He looks outside the field of healthcare to other industries to translate ideas, tools, and solutions into proactive, preventive approaches to medicine that foster health, wellness, performance, and longevity.Ravi creates value by:Delivering Accessible, Affordable Care – Ravi understands and addresses the problems of costly hospital-based care with digital innovations that provide access to people of every gender, race, age, and socioeconomic status. Translating Ideas into Real-World Solutions – Across a wide range of industries, Ravi connects with experts who have successfully ideated and released innovations in the real world. He reframes problems in healthcare and leverages solutions from other fields to move healthcare away from complex, narrow vision to new ways of thinking. Championing Improvements in Human Behavior – Ravi builds intelligent teams of experts and tech solutions that motivate behavior change, resulting in better health and enabling people to be their most productive, disease-free selves.In his current role as the Founder and CEO of Daytona Health, Ravi leads a network of experts to provide ultra-personalized coaching for behavior change and modification, resulting in improved health, longevity, and performance. Daytona Health leverages algorithms, advanced software, sensors, and human data to help its members achieve meaningful, measurable outcomes in metabolic disease, range of motion, energy levels, and stress management.Previously, Ravi co-founded and served as Chief Medical Officer for 2 digital health startups: Reflexion Health and Lumiata. He provided the product vision and clinical oversight to spinout a digital medicine, telehealth physical therapy solution – Reflexion Health – from the Scripps Research Institute and West Health Institute. This was one of the world's first motion tracking-enabled home virtual physical therapy platforms that pioneered the use of consumer devices for FDA-cleared healthcare...

Are supplements as strong as drugs? Dr. Tyler Panzner is this episode's guest, bringing his expertise on the role of genetics and supplements in combating common ailments such as IBS, anxiety, and insomnia.  As a champion for understanding our body's pathways, Dr. Panzner's approach is transforming our understanding of chronic disease and health management. Dr. Panzner dives deep into the crucial topic of understanding and supporting our body's most commonly mutated pathways, rather than getting caught up in an endless cycle of supplementing every gene. He also provides an exciting viewpoint, comparing gene mutations and their effects across all cells in the body. Joe and Tyler also point out the potential risks associated with the use of supplements and discuss the importance of understanding how they affect our bodies.  Dr. Tyler Panzner is a Ph.D. scientist trained in pharmacology, cancer, neuroscience, and inflammation research who has had a lifelong passion for understanding how substances affect the body. While his scientific training spans well over a decade, his passion for genetics and personalized medicine started ~6 years ago and he's pursued his goal of personalizing vitamin, supplement, and lifestyle regimes for each individual.  - Follow @drtylerpanzer on Instagram - visit www.drtylerpanzner.com - Check out SelfDecode - Join Joe's online community - Follow Joe on Instagram & TikTok

In this episode, Marc sits down with special guest Naveen Jain, a billionaire entrepreneur, philanthropist, and health-tech pioneer. Together, they dive deep into Naveen's mind and explore his journey to success, discussing his mindset, strategies, and habits that led him to become one of the most successful entrepreneurs in the world. He is the founder of several successful companies, including Moon Express, Viome, and Bluedot, to name a few.Naveen shares his insights on the importance of thinking big, taking risks, and embracing failure as a necessary step toward success. He also talks about the power of curiosity, creativity, and innovation in achieving breakthroughs in business and life.Join Marc and Naveen as they reveal the secrets of a billionaire entrepreneur's mind and provide valuable lessons that can help you unlock your own potential and achieve your goals. Get your copy of Personal Socrates: Better Questions, Better Life  Connect with Marc >>>  Website | LinkedIn | Instagram | Twitter Drop a review and let me know what resonates with you about the show!Thanks as always for listening and have the best day yet!*Behind the Human is proudly recorded in a Canadian made Loop Phone Booth*Special props

Episode Highlights With MattWhat wild health is and where this concept came fromHow a return to nature is the root of good healthWhat separates precision medicine from traditional medicineWhy genetics are important but they are only about 20% of the whole pictureThe importance of light, sleep, and stress for healthFactors we can optimize for our kids for lifelong healthAre diseases actually preventableWhat their data says on reversing disease through lifestyle interventionHis core pillars of optimal health and how to optimize each oneWhat studies say about movement and how much we needWhy he is also on team sardines as a superfoodThe reason to look at the calories vs nutrients equationHis personalized non-negotiables for healthWays to improve sleep qualityScience backed reasons to focus more on relationships and connection for better healthResources We MentionWild HealthOura RingChiliSleepLevels - Continuous Glucose MonitorLast Child in the Woods: Saving Our Children From Nature-Deficit Disorder by Richard LouvThe Bible (NIV)Awareness: Conversations with the Masters by Anthony de MelloThe 15 Commitments of Conscious Leadership: A New Paradigm for Sustainable Success by Jim DethmerThanks to Our Sponsors:Wellnesse - My line of personal care products such as toothpaste, deodorant, shampoo and much more!Timeline Nutrition - Mitopure from Timeline Nutrition offers an easy way to get your daily 500mg dose of Urolithin A, which helps with energy and endurance and so much more! Use code wellnessma for a discount.